The Age-Related Macular Degeneration (AMD) Market is entering a period of rapid expansion as cases of vision impairment rise worldwide. Valued at USD 11.47 Billion in 2025, the market is projected to grow at a robust CAGR of 9.70%, reaching USD 28.95 Billion by 2035. With the global population aging at an unprecedented rate, the demand for effective AMD therapies is increasing significantly.

Introduction: AMD Emerges as a Major Global Eye Health Challenge

Age-related macular degeneration is a progressive eye disorder that damages the macula—the part of the retina responsible for sharp, central vision. It is one of the leading causes of irreversible blindness among adults aged 50 and older. As longevity increases and lifestyle-related risk factors such as hypertension and smoking remain prevalent, AMD is becoming a critical public health concern.

In response, the global healthcare industry is intensifying research into advanced treatment modalities, including anti-VEGF injections, emerging gene therapies, and long-acting delivery systems. These innovations are significantly boosting the growth of the AMD treatment market.

Detailed Market Analysis

1. Rising Geriatric Population Drives Demand

With the global elderly population rapidly expanding, AMD incidence is increasing. The age bracket above 65 is particularly vulnerable, making this demographic trend a primary market driver.

2. Advances in Therapeutics Fuel Market Growth

Innovative treatments—especially anti-VEGF therapies such as ranibizumab and aflibercept—continue to dominate the AMD landscape. New long-duration and less-invasive solutions are also reshaping patient care.

3. Increasing Awareness and Diagnostic Improvements

Better screening technologies, such as OCT imaging and AI-based diagnostic tools, are enabling earlier disease detection, leading to improved treatment outcomes.

4. Growing Healthcare Infrastructure

Developing regions are investing in specialized ophthalmology care, making advanced AMD management more accessible than before.

5. Expanding Pipeline of Novel Therapies

Gene therapy platforms, sustained-release implants, and combination drug regimens are under development, promising to address unmet needs and reduce treatment burden.

Request your complimentary sample report featuring the complete TOC.

Key Companies Contributing to Market Expansion

Major global players shaping the AMD treatment market include:

Bayer AG

F. Hoffmann-La Roche Ltd.

Novartis AG

Regeneron Pharmaceuticals Inc. (REGN)

Others

These companies are investing in R&D, expanding product portfolios, and pursuing regulatory approvals to strengthen their presence in the global ophthalmology market.